score-matched hemodialysis (HD) patients. Incidence rates and hazard ratios (HRs) of PE and odds ratio (OR) of subsequent 30-day deaths from PE were evaluated among study cohorts by the end of 2011. Results. The overall incident PE was nearly 3-fold greater in dialysis patients than in the comparison cohort (0.92 versus 0.33 per 1000 person-years), with an adjusted HR of 2.02 [95% confidence interval (CI) ¼ 1.63-2.50]. The PE incidence was greater in the propensity score-matched HD patients, than in PD patients with an adjusted HR of 2.30 (95% CI ¼ 1. 23-4.29) . There was a greater PE risk for central venous catheter users than non-users among HD patients (1.83 versus 0.75 per 1000 person-years). The 30-day mortality from PE was higher in dialysis patients than in the comparison cohort (16.5 versus 9.77%) with an adjusted OR of 2.56 (95% CI ¼ 1.32-4.95). Conclusions. Dialysis patients are at a nearly 2-fold increased hazard of developing PE and are at greater risk of fatality from PE compared with those without clinical kidney disease. This study also shows a higher PE risk in HD patients than in PD patients.
Keywords: end-stage renal disease, hemodialysis, mortality, peritoneal dialysis, pulmonary embolism
I N T R O D U C T I O N
An earlier 25-year follow-up study in the USA found that the overall annual incidence rate of pulmonary embolism (PE) was $0.69 per 1000 person-years [1] . PE can have a devastating impact on patients, with an in-hospital mortality rate of up to 12% [2] . The disease is a major cause of death in hospitalized patients, leading to $30 000 deaths in the USA annually [2, 3] . In a study of pathogenesis of venous thromboembolism (VTE), Virchow has suggested that the occurrence of VTE is the result of impaired blood circulation, vascular endothelial injury and hypercoagulability [4] . Despite its association with bleeding tendency, chronic kidney disease (CKD) has been regarded as a hypercoagulable state because of underlying hemostatic derangements [5] [6] [7] [8] . Immobilization, intravascular device use, congestive heart failure, hyperhomocysteinemia, proteinuria and advanced age have also been associated with VTE [9] [10] [11] . The VTE risk is higher in patients with end-stage renal disease (ESRD) or CKD than in the general population [9] [10] [11] .
Several studies have demonstrated that patients with ESRD and CKD are at an increased risk of having PE, with the estimated relative risk varying widely [7, [12] [13] [14] . The risk of VTE has been found to be lower in Asians than in Caucasians, which is likely because of protective traits in Asians [15] . Although the VTE risk differs between Asians and Caucasians, the association between ESRD and VTE cannot be assumed to be the same between these two ethnic groups. There is so far no population study evaluating the PE risk for Asians with ESRD.
This study investigated the risk of PE in dialysis patients compared with people without clinical kidney disease using the claims data of National Health Insurance (NHI) Research Database of Taiwan. Dialysis modality may influence the outcomes of patients with ESRD [16] [17] [18] . We also attempted to compare the differences in the PE risk between different dialysis modalities and to evaluate the 30-day fatality of PE.
M A T E R I A L S A N D M E T H O D S

Data source
The Taiwan government launched the NHI program in 1995. Over 99% of the population of Taiwan have been under the NHI coverage since 1996 [19] . The NHI Research Database contains de-identified medical data to ensure patient anonymity. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes were used to identify all diseases diagnosed. This retrospective observational study complied with the guidelines of the Declaration of Helsinki and was approved by the Research Ethics Committee at China Medical University and Hospital (CMU-REC-101-012). The committee waived the need for informed consent because the patient privacy was protected in reviewing the existing data.
Study subjects
Patients with newly diagnosed ESRD (ICD-9-CM Code 585) from 1998 to 2010 were identified and were further classified into a peritoneal dialysis (PD) group and a hemodialysis (HD) group (Figure 1 ). Patients undergoing dialysis for at least 90 days were eligible to be included in the ESRD cohort. The 90th day after the initiation of dialysis was defined as the index date. The exclusion criteria included: (i) patients on PD or HD for <90 days; (ii) patients with a medical history of PE (ICD-9-CM Code 415.1) or renal transplantation (ICD-9-CM Code V42.0) before the index date; and (iii) patients aged <20 years. A comparison cohort was selected randomly from people with no history of kidney disease (ICD-9-CM Codes 580-589) and PE, frequency matched by age (every 5 years), sex and the index year of the dialysis patients. Each cohort included 106 231 persons. The ESRD cohort consisted of 98 891 HD patients and 7340 PD patients.
From the HD patients, we further selected 7340 patients matched by the propensity scores of PD patients, enabling adjustment for potential baseline confounders between the two dialysis modalities (Figure 1 ). We used a logistic regression model to estimate the propensity score based on the baseline variables of age, sex, comorbidities, warfarin use and the year of dialysis initiation. The baseline comorbidities included coronary artery disease (CAD) (ICD-9-CM Codes 410-413, 414.01-414.05, 414.8 and 414.9), diabetes (ICD-9-CM Code 250), stroke (ICD-9-CM Codes 430-438), hyperlipidemia (ICD-9-CM Code 272), atrial fibrillation (AF) (ICD-9-CM Code 427.31), hypertension (ICD-9-CM Codes 401-405), congestive heart failure (CHF) (ICD-9-CM Codes 428, 398.91 and 402.x1), cancer (ICD-9-CM Codes 140-208) and systemic lupus erythematous (SLE) (ICD-9-CM Code 710.0).
All participants were followed-up from the index date to the date when PE was diagnosed or until the end of 2011. Patients who died, withdrew from the insurance program or received renal transplantation were censored.
Statistical analysis
Distributions of baseline characteristics between the ESRD and comparison cohorts and between the HD and PD patients were evaluated using the Chi-square test to examine the categorical data. Differences in mean ages were examined by t-test. Cox proportional hazards models were used to estimate hazard ratios (HRs) of PE and 95% confidence intervals (CIs). Variables with a P-value <0.05 in the univariate Cox proportional hazards model were included for further analysis in the multivariate Cox model. Because the mortality rates were different between ESRD and comparison cohorts, we used the multivariate competing-risk regression model to assess the subhazard ratio (SHR) and 95% CI of PE. We further compared the incidence and HR of PE between patients with and without the use of central venous catheter in the HD cohort. Logistic regression analysis was used to measure odds ratios (ORs) and 95% CIs of 30-day mortality for patients with PE. All analyses were performed using SAS statistical software version 9.4 for Windows (SAS Institute Inc., Cary, NC, USA). The significance level was set at 2-sided for P < 0.05.
R E S U L T S
During the follow-up period, 413 dialysis patients developed PE, and 2816 (2.9%) HD patients and 639 (8.7%) PD patients received renal transplantation (data not shown). There were 5521 (5.2%), 46 653 (47.2%) and 2190 (29.8%) deaths in the comparison, HD and PD cohorts, and 10 220 (9.6%), 5087 (5.1%) and 195 (2.7%) persons lost to follow-up due to withdrawal from the insurance in these three groups, respectively. The mean follow-up periods were 6.18 6 3.75, 4.23 6 3.26 and 4.19 6 2.98 years in the comparison, HD and PD cohorts, respectively. Table 1 lists the baseline characteristics of the study groups. Comorbidities and warfarin use were more prevalent in dialysis patients than in the comparison cohort (all P < 0.0001). In the ESRD cohort, patients on PD were younger and comprised of a higher proportion of women than those on HD (P < 0.0001). CAD, diabetes, stroke, AF, hypertension, CHF, cancer and warfarin use were more prevalent in the HD cohort than in the PD cohort. However, the prevalence of SLE in PD patients was approximately three times higher than that in HD patients (2.51
The flow chart for study subjects. ESRD, end-stage renal disease; PD, peritoneal dialysis; HD, hemodialysis.
versus 0.86%, P < 0.0001). Table 1 also shows that the propensity score-matched HD and PD subcohorts were alike in all variables. Table 2 shows the incidence of PE was nearly 3-fold greater in dialysis patients than in the comparison cohort (0.92 versus 0.33 per 1000 person-years) with an adjusted HR of 2.02 (95% CI ¼ 1.63-2.50). In the multivariate competing-risk model, the adjusted SHR of PE for ESRD patients reduced to 1.26 (95% CI ¼ 1.04-1.53), compared with non-ESRD patients. The hazard of PE was higher in women (adjusted HR ¼ 1.19, 95% CI ¼ 1.01-1.39) than in men and increased with age. The PE hazards were also associated with comorbidities of CAD (adjusted HR ¼ Table 3 lists the stratum-specific HRs of PE for the ESRD cohort relative to the comparison cohort by age, sex and comorbidities. For each age-and sex-specific stratum, both adjusted HR and SHR of PE showed that dialysis patients were at an increased hazard to have PE. Greater hazards were observed for dialysis patients without any comorbidity. However, dialysis patients with CAD, AF, CHF and cancer had lower SHR of PE compared with the comparison cohort, but this was significant only for CHF.
The incidence of PE in the propensity score-matched HD cohort was 2.3-fold greater than that in the PD cohort (Table 4 ). The adjusted SHR increased slightly to 2.39 (95% CI ¼ 1.28-4.47) in the multivariate competingrisk model.
Among HD patients, there were 24.1% users of the central venous catheter (Table 5 ). The incidence of PE was 2.4-fold greater in catheter users than in non-users (1.83 versus 0.75 per 1000 person-years), with an adjusted HR of 2.37 (95% CI ¼ 1.92-2.92) or with a SHR of 2.32 (95% CI ¼ 1.89-2.86) in competing-risk analysis. Table 6 shows the 30-day mortality for subjects who had developed PE. The mortality rate was greater in the ESRD cohort than in the comparison cohort (16.5 versus 9.77%) with an adjusted OR 2.56 (95% CI ¼ 1.32-4.95) for dialysis patients, mainly in the HD cohort.
D I S C U S S I O N
The present study demonstrated that the overall incidence rate of PE was near 3-fold greater in the dialysis patients than in the comparison cohort. The risk of PE for dialysis patients remained significant in competing-risk models after controlling for deaths (adjusted HR 1.26, 95% CI ¼ 1.04-1.53). In addition, HD patients were more likely to develop PE compared with PD patients (HR ¼ 2.30, 95% CI ¼ 1. 23-4.29) . The ESRD patients also had an increased fatality from PE with an adjusted OR of 2.56 relative to the comparison cohort. 
In an earlier study in the USA, Tveit et al. found the incidence of PE occurring within 1 year of dialysis initiation was nearly 6-fold greater in dialysis patients than in the general population (1.49 versus 0.25 per 1000 person-years) [14] . A recent nationwide study in the USA revealed that the annual incidence rates of PE were 5.27, 2.04 and 0.66 per 1000 persons per year for patients with ESRD, CKD and persons with normal kidney function, respectively [12] . Consistent with the findings in previous studies, our study showed a nearly two-fold increased adjusted HR of PE in dialysis patients. In addition, the incidence of PE in Taiwan is lower than that in the USA, likely because of the lower risk of VTE in Asian people [15] .
The present study demonstrated that ESRD, older age, female gender, CAD, AF, hypertension, CHF and SLE were risks factors for PE. However, among people with CAD, AF, CHF and cancer, the hazards of PE were lower for dialysis patients than for the comparison cohort. These comorbidities may mediate slightly the association between ESRD and PE, but mostly not significantly. A higher rate of hospitalization, surgery, immobilization and cardiovascular disease could explain the higher risk of PE in dialysis patients.
Increased procoagulant factor levels may enhance activation and aggregation of platelets. Reduced endogenous anticoagulants and fibrinolytic activity also contribute to hypercoagulability in patients with CKD and ESRD [5] [6] [7] [8] . Furthermore, erythropoietin-stimulating agents can increase the risk of thromboembolism [20] . Although proteinuria can increase the risk of VTE [21, 22] , diminished urine output and the subsequent decline in proteinuria and urinary loss of antithrombin III may alleviate hypercoagulability in dialysis patients.
The present study demonstrated that HD patients had a higher risk of PE than PD patients did. In addition, the risk [23] . A recent study in the Netherlands reported that HD was associated with an increased risk of venous thrombosis compared with PD, although this finding was not significant (HR ¼ 2.6, 95% CI ¼ 0.7-9.7) [24] . Several factors may explain the higher risk of PE in HD patients than in PD patients. Thrombus formation in catheters and arteriovenous accesses in HD patients may cause PE through the dislodging of blood clots [25, 26] . However, clinically symptomatic PE following percutaneous repair of a thrombosed dialysis shunt is rare, occurring in 0-5% of patients [5, 25] . Although HD patients are intermittently heparinized, 4-h immobilization for dialysis three times per week may contribute to a higher risk of PE. In addition, the HD procedure enhances procoagulant and platelet activities [5, [27] [28] [29] . Plasma levels of endogenous anticoagulants, such as protein C, protein S and antithrombin III, are lower in HD patients than in PD patients [30] . The present study revealed that the 30-day mortality from PE was higher in dialysis patients than in the comparison cohort. In a prospective registry study, Monreal et al. reported that the OR of death from PE in patients with creatinine clearance rate of <30 ml/min could be as high as 5.2 (95% CI ¼ 3.4-7.8), compared to subjects with the rate of >60 ml/min [13] . A recent study in the USA revealed that patients with CKD and ESRD admitted for PE had a higher inhospital mortality rate [12] . Reduced cardiopulmonary reserve in dialysis patients might increase PE fatality. The strength of this study is the use of a large population data set with well-matched cohorts to reduce the confounding effects. Although we did not validate diagnostic codes for PE, the high reliability of the diagnostic codes of this database has been reported [31, 32] . In addition, the NHI has established mechanisms to audit claims data randomly to avoid violation. However, the present study has several limitations. First, the database provided limited or no information on lifestyles and sociodemographic characteristics such as body mass index, smoking habits and functional status. Obesity and smoking are risk factors for PE [9, 11] . Second, no information was available on laboratory data such as hemoglobin and albumin levels, residual renal function and dialysis adequacy. These variables could not be adjusted for in the data analyses. However, the indication of dialysis was audited under the NHI program; thus the residual renal function at the start of dialysis might not be different between HD and PD patients. The NHI program also audited the quality of dialysis to ensure adequacy. Third, the results of scintigraphy and angiography examinations, and clinical symptoms were not included in the claims database. However, from the procedure codes, we were able to identify that 73.4% of dialysis patents and 66.5% of the comparison cohort diagnosed with PE had ever received computed tomography scan or ventilation-perfusion scan (data not shown). In addition, the incidence of PE in the comparison cohort was comparable to that in people of similar age reported from China and Korea [33, 34] . Thus, the diagnosis of PE was reliable in this database. Finally, because only one mortality case was reported in the PD group, we could not compare the fatality risk from PE between PD patients and HD patients. Furthermore, a selection bias may occur for one modality over another. However, we matched the patients using propensity scores, which could reduce the selection bias.
In conclusion, dialysis patients have a nearly 2-fold increased hazard ratio of PE and a 2.5-fold increased fatality from PE compared with those without clinical kidney disease. In addition, HD is associated with a higher risk of PE than PD. Appropriate preventive measures are required to reduce the potential PE development and to avoid PE fatality.
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